Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1927 of 6351
-
New hope for young hemophilia patients: jivi safety trial shows promise for fewer injections
Disease control CompletedResearchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood. People with hemophilia A may bleed for a long time from minor wounds, have …
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a cholesterol drug boost immunotherapy in lung cancer?
Disease control Stopped earlyThis is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer). Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs…
Phase 2 • Sponsor: Eziafa Oduah, MD, PhD, MPH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Real-World data sought on ibalizumab for Tough-to-Treat HIV
Disease control CompletedThe virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogene…
Sponsor: Theratechnologies • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a simple blood test guard against organ damage in heart surgery?
Knowledge-focused OngoingStudying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB a…
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
New combo therapy for chronic migraine: atogepant plus botox under study
Disease control CompletedMigraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the …
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a brain injury coach keep ex-inmates from returning to prison?
Disease control OngoingThe purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy targets Hard-to-Treat bile duct cancer
Disease control OngoingThe purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Phase 1/2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immune cell boost could keep leukemia at bay after transplant
Disease control OngoingThe purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with A…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
MRI scans may help prevent intestinal damage in Crohn's disease
Disease control Recruiting nowCrohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can dramatically affect the quality of life of patients. Due to its transmural nature (involvement of the entire thickness of the intestinal wall), it naturally progresses to intestinal destruction (stenosis,…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug cocktail aims to tame rare liver disease
Disease control CompletedStudy to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
Phase 2 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a 3-Day course ease chronic fatigue? new trial aims to find out
Symptom relief Recruiting nowChronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal proble…
Sponsor: Norwegian University of Science and Technology • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Can an Iron-Binding drug protect the brain after a severe stroke?
Disease control Recruiting nowAneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the r…
Phase 2 • Sponsor: Aditya S. Pandey, MD • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Fourth COVID shot may shield seniors from severe illness
Disease control CompletedThe objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly. There are an estimated 490,000 eligible individuals aged 60 and over statewide for the effectiveness study. Two hundred …
Sponsor: Federal University of Espirito Santo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New scan could spot deadliest prostate cancers
Diagnosis OngoingCD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRP…
Phase 1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New antibody shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThe study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Robot suit and zaps may boost walking after spinal injury
Symptom relief Recruiting nowWhile there are a number of prospective studies evaluating powered exoskeletons in SCI patients, to date, not a single well-designed, randomized clinical trial has been published. However, there is evidence for beneficial effects of over-ground exoskeleton therapy on walking func…
Sponsor: Mario Widmer • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise against rare skin cancer
Disease control OngoingThis phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a simple pill calm brain inflammation and slow Alzheimer's?
Disease control Recruiting nowDevelopment of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove b…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for adults with rare leukemia: drug combo shows promise in early trial
Disease control OngoingThis phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may stop the growth of cancer cel…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy aims to tame stem cell transplant complications
Disease control CompletedThis is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
Phase 1/2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC